Daiichi Sankyo stock
4568.TJPXDaiichi Sankyo Company, Limited, HealthcareISIN JP3475350009
71Score 71 out of 100, Strong
Price and trend
64 / 100
Price history
−18% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 2.8% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 26% below its 52-week high. Largest decline in 20 years: 70% (February 2007 to October 2012).
Chart figures for advanced users
- SMA 50$17.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.46
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.02
- The lowest closing price of the last twelve months.
- Resistance$24.27
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Daiichi Sankyo Company, Limited belongs to the Drug Manufacturers (General) industry (Japan) and, with a market value of $32.7B, is number 19 of 27 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $13.33B (up 12.6% year on year) and earnings of $1.63B (down 12.1%).
- For fiscal 2027, analysts expect on average revenue of $14.88B (up 11.6%) and adjusted earnings per share of $0.93 (up 5.4%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 108 of 714 in Healthcare, median 53.
- The P/E is 18.8 (Drug Manufacturers (General) median 17.3, own median of recent years 38.4).
- Our model puts fair value at $23.25, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 29.1% a year since 2021.Growth 72
- Below fair valuePrice 25% below the fair value of $23.25.Valuation 76
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 69
Weaknesses
- Margin fallingOperating margin 9.8%, average of the prior years 13.3% (to 2025).
Its standout strengths are capital allocation and stability, while momentum holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 73 to 71.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $17.88 and expensive above $33.21 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $29.95 (cash-flow model) and $16.55 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $20.47, at 5.1% it would be $27.43.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (17.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17% on the twelve months before. Revenue has grown solidly since 2007, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 68%, operating 10%, net 12%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 29 Jan 2027in 78 days
- Last reported
- 30 Oct 2026EPS reported $0.29 (expected $0.24)above expectations
Analyst estimates
Earnings estimates have barely changed since 23 Oct 2026.
- Earnings per share
- $0.93+1.0%
- Revenue
- $14.88B+0.1%
- Earnings per share
- $1.21+0.9%
- Revenue
- $15.1B−0.2%
MEQIRI has stored the estimates since 23 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Daiichi Sankyo
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Chugai Pharmaceutical4519.T $73.85B78
- BayerBAYN.DE $62.05B53
- Otsuka Holdings4578.T $39.66B78
- BiogenBIIB $37.46B60
- Astellas Pharma4503.T $29.67B87
- OrionORNBV.HE $16.06B86
- CSPC Pharmaceutical Group1093.HK $12.4B79
- Zhangzhou Pientzehuang Pharmaceutical.600436.SS $11.78B58
ETFs that hold Daiichi Sankyo
Held by 108 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS MSCI Japan Socially Responsible UCITS ETF JPY disFRCJ | 2.35% | 0.19% | €523.43M |
| iShares MSCI Japan SRI UCITS ETFSXR6 | 2.09% | 0.20% | €434.77M |
| UBS MSCI Japan Climate Paris Aligned UCITS ETF ir-hEUR accAW1Q | 1.85% | 0.15% | €191.34M |
Show 5 more
| UBS MSCI Pacific Socially Responsible UCITS ETF USD disUIMT | 1.75% | 0.28% | €751.57M |
| Xtrackers MSCI Japan ESG UCITS ETF 1CXZMJ | 1.30% | 0.20% | €2.69B |
| Amundi MSCI Japan SRI Climate Paris Aligned UCITS ETF DR Hedged EUR (D)JPNE | 1.24% | 0.20% | €500.27M |
| Deka MSCI Japan Climate Change ESG UCITS ETFEL45 | 1.03% | 0.26% | €162.3M |
| WisdomTree Japan Equity UCITS ETF USD HedgedWTDX | 0.86% | 0.48% | €796.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ¥159.23)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.